Human neutralising antibodies elicited by SARS-CoV-2 non-D614G variants offer cross-protection against the SARS-CoV-2 D614G variant

Lee, CYP; Amrun, SN; Chee, RSL; Goh, YS; Mak, TM; Octavia, S; Yeo, NKW; Chang, ZW; Tay, MZ; Torres-Ruesta, A; Carissimo, G; Poh, CM; Fong, SW; Bei, W; Lee, S; Young, BE; Tan, SY; Leo, YS; Lye, DC; Lin, RT; Maurer-Stroh, S; Lee, BE; Wang, CI; Renia, L; Ng, LF

Renia, L; Ng, LF (corresponding author), ASTAR, A STAR ID Labs, 8A Biomedical Grove,Immunos 04-06, Singapore 138648, Singapore.

CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2021; 10 (2):

Abstract

Objectives. The emergence of a SARS-CoV-2 variant with a point mutation in the spike (S) protein, D614G, has taken precedence over the original Wuhan ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索